- Posted Friday July 31, 2020
UArizona-TGen led team identifies new biomarkers to diagnose and monitor brain injuries
Integrated protein and metabolite analysis open the door to more precise ways of guiding treatment for the nearly 70 million people worldwide who annually suffer traumatic brain injuries
PHOENIX, Ariz. — July 31, 2020 — A scientific team led by the University of Arizona and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, identified a robust set of biomarkers through proteomics and metabolomic analysis that could help guide treatment for tens of millions of patients who each year sustain brain injuries, potentially preventing severe long-term disabilities.
The team’s findings were reported in a study published today in the Nature journal: Scientific Reports.
An estimated 69 million people worldwide annually sustain traumatic brain injury (TBI). That includes at least 3 million in the U.S., resulting in nearly 288,000 hospitalizations, 56,800 deaths and more than 90,000 with permanent disabilities.
One of the practical applications of the study was to show the effectiveness of a treatment for brain injuries known as RIC (Remote Ischemic Conditioning). RIC involves, for example, using a tourniquet to restrict, then release, the flow of blood in one of the head-injury patient’s arms or legs. Scientists still don’t know why, but circulating molecules in the bloodstream are produced that could help the brain minimize or repair the injury through this seemingly unrelated technique of on-again, off-again flow of oxygen and nutrients to a patient’s limb.
“The molecules released by alternately restricting and releasing the blood flow seem to have a neuro-protective effect,” said Dr. Patrick Pirrotte, Director of TGen’s Collaborative Center for Translational Mass Spectrometry and one of the study’s senior authors.
Using mice models and TGen’s state-of-the-art mass spectrometry facility to analyze proteins and metabolites, Dr. Pirrotte’s team identified biomarkers that showed the effectiveness of RIC, and additional biomarkers that could be used to measure the presence of the injury.
Premature return to normal or strenuous activities can worsen the (TBI) condition and induce chronic health-related issues, the study says, further exacerbating the onset of neurodegenerative diseases.
“The biomarkers we identified allow us to measure the extent of the injury, and monitor RIC-aided recovery from brain injury,” said Dr. Khyati Pathak, a member of Dr. Pirrotte’s team and one of the study’s authors.
The newly-identified biomarkers can provide a more exacting, molecular-level diagnosis of TBI.
“Traumatic brain injury, particularly in its less severe form, may not seemingly require hospitalization or an emergency room visit,” said Dr. Jonathan Lifshitz, Director of the UArizona’s Translational Neurotrauma Research Program: a joint venture between the UArizona College of Medicine-Phoenix; a branch of Barrow Neurological Institute at Phoenix Children’s Hospital; and the Phoenix VA Health Care System.
“For millions of individuals, there often is no health care access immediately after TBI events, whether it be organized sports, recreational activities, occupational hazards, military service, or domestic violence,” said Dr. Lifshitz, one of the study’s senior authors.
The use of RIC — the alternating restriction and release of blood flow to an arm or leg — has been shown in clinical studies to be effective in other emergency medical situations, including cardiac arrest, organ transplantation, and lung injury.
“RIC is an easy to teach, practical intervention for a brain injury outside of the hospital setting. It allows for immediate care to the patient with the intent to reduce brain injury pathology,” said Dr. Maha Saber, who is affiliated with Barrow and UArizona and is the study’s lead author.
This research study — Proteomic analysis identifies plasma correlates of remote ischemic conditioning in the context of experimental traumatic brain injury — was funded by grants from the National Institutes of Health (NIH-R21-NS096515, F31-NS090921, and T32-AG044402).
# # #
About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
TGen Senior Science Writer